TIM3 CAR T cells

TIM3 CAR T cells are a research-stage class of chimeric antigen receptor (CAR) T-cell therapies designed to target **T-cell immunoglobulin and mucin-domain containing-3 (TIM3)**, also known as **Hepatitis A virus cellular receptor 2 (HAVCR2)**. TIM3 is a surface protein significantly overexpressed on leukemia stem cells (LSCs) in **acute myeloid leukemia (AML)** and myelodysplastic syndromes, while remaining largely absent on healthy hematopoietic stem and progenitor cells (HSPCs). This differential expression makes TIM3 an attractive target for reducing on-target/off-tumor toxicities, such as prolonged myelosuppression, which is a common challenge with other myeloid targets like CD33. Current research, including work presented by institutions like **LMU Munich**, explores various CAR architectures, including single-target constructs and dual-targeting split or tandem CARs (e.g., CD33-TIM3) to further refine specificity and potency against refractory AML.

Other names

TIM-3 CAR-TTIM3 CAR-TTIM 3 CAR-TTIM3-directed CAR T cellsTIM-3-directed CAR T cellsTIM 3-directed CAR T cellsanti-TIM3 CAR T cellsanti-TIM-3 CAR T cellsanti-TIM 3 CAR T cells